Jasper Therapeutics, Inc.
NASDAQ: JSPR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeetinder Singh Mahal
- Employees
- 22
- Headquarters
- Redwood City, United States
- IPO year
- 2020
- Market cap
- $8.0M
- Website
- https://jaspertx.com
Loading JSPR…
Loading profile data…Frequently asked questions about JSPR
What does Jasper Therapeutics, Inc. (JSPR) do?
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem c...
Where does JSPR trade?
Jasper Therapeutics, Inc. (JSPR) trades on the NASDAQ.
What sector is JSPR in?
Jasper Therapeutics, Inc. (JSPR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Jasper Therapeutics, Inc.?
Jeetinder Singh Mahal is the chief executive officer of Jasper Therapeutics, Inc. (JSPR).
Where is Jasper Therapeutics, Inc. headquartered?
Jasper Therapeutics, Inc. is headquartered in United States.
Does JSPR pay a dividend?
Jasper Therapeutics, Inc. (JSPR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did JSPR go public?
Jasper Therapeutics, Inc. (JSPR) completed its initial public offering in 2020.